HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

YMAB

Y-Mabs Therapeutics Inc

Last Close
Jul 11 • 04:00PM ET
4.36
Dollar change
-0.16
Percentage change
-3.54 		%
Healthcare • Biotechnology • USA • NASD
Peers: BMRN CLLS BLUE ADAP AGEN SRPT MRNA GSK TGTX XOMA
 | Held by: VTI IWM VXF IWO IBB VTWO SCHA VHT IWC DFAS
Scroll to Statements
IndexRUT P/E- EPS (ttm)-0.63 Insider Own25.16% Shs Outstand45.25M Perf Week1.40%
Market Cap197.49M Forward P/E- EPS next Y-1.06 Insider Trans-0.13% Shs Float33.90M Perf Month-14.68%
Enterprise Value137.78M PEG- EPS next Q-0.26 Inst Own58.85% Short Float7.61% Perf Quarter-2.02%
Income-28.23M P/S2.23 EPS this Y-47.16% Inst Trans-0.27% Short Ratio12.46 Perf Half Y-43.01%
Sales88.66M P/B2.21 EPS next Y-7.10% ROA-23.93% Short Interest2.58M Perf YTD-44.32%
Book/sh1.98 P/C3.27 EPS next 5Y-17.97% ROE-29.93% 52W High16.11 -72.94% Perf Year-61.31%
Cash/sh1.33 P/FCF- EPS past 3/5Y19.44% 21.90% ROIC-31.51% 52W Low3.55 22.82% Perf 3Y-75.63%
Dividend Est.- EV/EBITDA- Sales past 3/5Y35.95% - Gross Margin82.06% Volatility6.03% 7.52% Perf 5Y-89.78%
Dividend TTM- EV/Sales1.55 EPS Y/Y TTM-27.70% Oper. Margin-34.78% ATR (14)0.32 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.35 Sales Y/Y TTM4.92% Profit Margin-31.84% RSI (14)45.39 Recom1.58
Dividend Gr. 3/5Y- - Current Ratio4.77 EPS Q/Q23.91% SMA20-4.81% Beta0.56 Target Price14.58
Payout- Debt/Eq0.01 Sales Q/Q4.88% SMA50-2.47% Rel Volume0.54 Prev Close4.52
Employees107 LT Debt/Eq0.00 EarningsMay 13 BMO SMA200-42.59% Avg Volume206.87K Price4.36
IPOSep 21, 2018 Option/ShortYes / Yes EPS/Sales Surpr.43.45% 6.69% Trades Volume111,066 Change-3.54%
Date Action Analyst Rating Change Price Target Change
Apr-22-25Downgrade BofA Securities Neutral → Underperform $3
Nov-18-24Initiated Oppenheimer Outperform $23
Aug-16-24Initiated Cantor Fitzgerald Overweight $20
Jun-28-24Initiated Truist Buy $21
May-10-23Upgrade Wedbush Neutral → Outperform $5 → $13
Apr-03-23Downgrade Guggenheim Buy → Neutral
Jan-27-23Downgrade Morgan Stanley Equal-Weight → Underweight $4
Jan-05-23Downgrade Cowen Outperform → Market Perform
Dec-02-22Downgrade BofA Securities Buy → Neutral $23 → $5
Dec-02-22Downgrade BofA Securities Buy → Neutral
Show Previous Ratings
May-28-25 06:35AM
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
(GlobeNewswire)
May-26-25 10:57PM
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
(Insider Monkey)
10:00AM
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
(GlobeNewswire)
May-14-25 09:18AM
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
(TipRanks) -12.50%
03:05AM
Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
(GuruFocus.com)
10:29PM Loading…
May-13-25 10:29PM
Q1 2025 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
07:05AM
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
(GlobeNewswire)
06:35AM
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
(GlobeNewswire)
May-12-25 09:43AM
Earnings To Watch: Y-mAbs Therapeutics Inc (YMAB) Reports Q1 2025 Result
(GuruFocus.com)
08:15AM
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
May-09-25 08:35AM
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
May-07-25 06:15PM
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
(Zacks)
09:06AM
Y-mAbs gets NCCN recommendation for neuroblastoma treatment
(Seeking Alpha)
07:05AM
Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA)
(GlobeNewswire)
07:05AM Loading…
May-06-25 07:05AM
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
(GlobeNewswire) -9.18%
Apr-30-25 10:01AM
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
(Zacks)
Apr-29-25 10:01AM
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
(Zacks)
Apr-27-25 03:00PM
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
(GlobeNewswire)
Apr-25-25 07:35AM
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
(GlobeNewswire)
Apr-11-25 04:35PM
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity
(Seeking Alpha) +11.03%
Mar-05-25 02:04AM
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ...
(GuruFocus.com)
01:34AM
Q4 2024 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-04-25 07:50AM
Y-mAbs announces publication of Phase 2 interim results on naxitamab
(TipRanks)
07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Mar-03-25 07:30AM
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
(GlobeNewswire) -6.65%
07:21AM
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Report Preview: What To Look For
(GuruFocus.com)
Feb-25-25 10:00AM
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
(Zacks)
Feb-20-25 04:05PM
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
(GlobeNewswire) -5.92% -5.30%
07:30AM Loading…
Feb-06-25 07:30AM
Y-mAbs to Present at the Oppenheimer 35 Annual Life Sciences Conference
(GlobeNewswire)
Feb-04-25 09:35AM
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Feb-03-25 09:35AM
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-31-25 07:35AM
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
(GlobeNewswire)
Jan-11-25 09:49AM
Y-mAbs Therapeutics Announces Strategic Business Realignment
(TipRanks)
Jan-10-25 09:26AM
Correcting and Replacing Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire) -6.77%
09:26AM
Correcting & Replacing Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire)
07:35AM
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
(GlobeNewswire)
07:05AM
Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire)
Jan-08-25 07:25AM
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
(TipRanks)
Dec-23-24 07:30AM
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-15-24 06:04AM
Oppenheimer Predicts Up to ~580% Jump for These 2 Strong Buy Stocks
(TipRanks)
Dec-07-24 12:00PM
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
(GlobeNewswire)
Nov-27-24 07:35AM
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
(GlobeNewswire) +10.31%
Nov-09-24 06:01AM
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
(GuruFocus.com)
Nov-08-24 07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Nov-07-24 07:08AM
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings
(GuruFocus.com)
Nov-04-24 07:35AM
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA (naxitamab-gqgk) in Japan
(GlobeNewswire)
Nov-01-24 10:00AM
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Oct-25-24 07:05AM
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
(GlobeNewswire)
Oct-09-24 06:12PM
Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...
(GuruFocus.com)
Oct-01-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in October
(GlobeNewswire)
Sep-06-24 07:30AM
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
(GlobeNewswire)
Sep-03-24 08:32AM
Y-mAbs to Participate in Upcoming Investor Conferences in September
(GlobeNewswire)
Aug-12-24 06:33PM
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
(Motley Fool) -11.24% +8.74%
07:40AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
06:30AM
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Aug-09-24 07:20AM
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners Top Holdings Now?
(Insider Monkey)
Aug-07-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in August
(GlobeNewswire)
Aug-05-24 04:05PM
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
(GlobeNewswire) -6.27%
Jul-01-24 04:05PM
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
(GlobeNewswire)
Jun-07-24 07:05AM
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
(GlobeNewswire)
Jun-05-24 07:05AM
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
(GlobeNewswire) +5.91%
Jun-01-24 08:15AM
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
(GlobeNewswire)
08:05AM
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
(GlobeNewswire)
May-09-24 11:58AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
(Insider Monkey) -5.44%
03:04AM
Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 09:57PM
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -20.92%
May-07-24 09:55PM
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace)
06:12PM
Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
(GuruFocus.com)
05:55PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Apr-26-24 07:05AM
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
(GlobeNewswire)
Apr-25-24 04:05PM
Y-mAbs to Present at 2024 ASCO Annual Meeting
(GlobeNewswire)
Mar-28-24 09:55AM
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
(Zacks)
Mar-20-24 07:37AM
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
(Zacks)
Mar-14-24 09:05AM
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
(GlobeNewswire) -5.30%
Mar-12-24 09:55AM
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
(Zacks)
Mar-05-24 12:00PM
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
(Zacks)
Mar-04-24 08:45AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
(Insider Monkey) -7.28%
07:30AM
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
(GlobeNewswire)
Mar-01-24 09:42PM
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) +11.92%
Feb-29-24 05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
04:37PM
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023
(GuruFocus.com)
04:05PM
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Feb-22-24 10:00AM
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
(Zacks)
Feb-16-24 07:30AM
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
(GlobeNewswire)
Feb-13-24 04:10AM
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
(Zacks)
Jan-02-24 04:05PM
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-13-23 04:05PM
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
(GlobeNewswire)
Dec-12-23 01:05AM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc
(GuruFocus.com)
Dec-03-23 03:04AM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc
(GuruFocus.com)
Nov-30-23 11:04PM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB)
(GuruFocus.com)
Nov-15-23 01:14PM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript
(Insider Monkey)
01:33AM
Q3 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Nov-13-23 05:31PM
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational Streamlining
(GuruFocus.com) +9.84%
05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
04:05PM
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Nov-08-23 12:00PM
All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy
(Zacks)
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gad ThomasCHIEF BUSINESS OFFICERJun 03 '25Option Exercise2.00103,000206,000305,721Jun 05 07:17 PM
Rossi Michael JPRESIDENT & CEOMar 07 '25Sale5.203,91720,368137,083Mar 11 08:17 PM
Gad ThomasCHIEF BUSINESS OFFICERMar 07 '25Sale5.2310,81056,536202,721Mar 11 08:15 PM
Rajah VigneshOfficerMar 07 '25Proposed Sale5.204,94625,743Mar 07 04:40 PM
Smith Susan LauraOfficerMar 07 '25Proposed Sale5.265,52829,100Mar 07 04:36 PM
Gad ThomasOfficerMar 07 '25Proposed Sale5.2310,81056,547Mar 07 04:32 PM
Rossi Michael JOfficerMar 07 '25Proposed Sale5.203,91720,388Mar 07 04:26 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 19 '24Option Exercise4.3822,831100,000181,531Sep 20 04:15 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 13 '24Sale13.4765,000875,55097,681Sep 17 08:05 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 16 '24Sale12.9730,000389,10067,681Sep 17 08:05 PM
Thomas GadOfficerSep 13 '24Proposed Sale13.74100,0001,374,000Sep 13 04:19 PM
Ber GerardDirectorSep 03 '24Proposed Sale13.8313,950192,928Sep 03 05:00 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Option Exercise4.3850,000219,00085,600Aug 30 04:15 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Sale15.3750,000768,50035,600Aug 30 04:15 PM
Lund-Hansen TorbenOfficerAug 28 '24Proposed Sale15.3750,000768,432Aug 28 05:12 PM
Wilms JorisSVP & CHIEF OPERATING OFFICERAug 26 '24Sale14.695,00073,45030,600Aug 27 05:05 PM
Wilms JorisOfficerAug 26 '24Proposed Sale14.695,00073,450Aug 26 04:12 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.